Prognostic value of serum markers for prostate cancer

Scandinavian Journal of Urology and Nephrology, Supplement

Volumn 39, Issue 216, 2005, Pages 64-81

  Stenman, Ulf Håkan ^a   Abrahamsson, Per Anders ^b   Aus, Gunnar ^c   Lilja, Hans ^d   Bangma, Chris ^e   Hamdy, Freddie C ^f   Boccon Gibod, Laurent ^g   Ekman, Peter ^h  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^f ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^g BICHAT HOSPITAL   (France)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Diagnosis; Follow up; Prognosis; Prostate cancer; Serum markers; Treatment

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; ANDROGEN; BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; CHROMOGRANIN A; HK2 ANTIGEN; LEPTIN; NEURON SPECIFIC ENOLASE; OSTEOCALCIN; OSTEOPROTEGERIN; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CELL RECEPTOR; CHROMOGRANIN; COLLAGEN TYPE 1; ENOLASE; GLYCOPROTEIN; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N TERMINAL PEPTIDE; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE; TISSUE KALLIKREIN; TNFRSF11B PROTEIN, HUMAN; TUMOR MARKER; TUMOR NECROSIS FACTOR RECEPTOR;

ALGORITHM; ANDROGEN ABLATION; ARTIFICIAL NEURAL NETWORK; BLOOD CHEMISTRY; BONE METABOLISM; CANCER DIAGNOSIS; CANCER GRADING; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CASE FINDING; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; HORMONE SENSITIVITY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; NEUROENDOCRINE DIFFERENTIATION; NON INVASIVE MEASUREMENT; ORGAN SIZE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE SIZE; RELIABILITY; TUMOR DIFFERENTIATION; TUMOR GROWTH; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CANCER RADIOTHERAPY; CELL DIFFERENTIATION; DISEASE MARKER; FOLLOW UP; METASTASIS; NEUROSECRETORY CELL; PROSTATECTOMY; TUMOR VOLUME; AGED; BIOPSY; BLOOD; BONE TUMOR; CARCINOMA; DISEASE COURSE; METABOLISM; MIDDLE AGED; PATHOLOGY; PREVALENCE; PROBABILITY; PROSTATE TUMOR; REVIEW;

AGED; ALKALINE PHOSPHATASE; ANDROGENS; BIOPSY; BONE NEOPLASMS; CARCINOMA, NEUROENDOCRINE; CHROMOGRANIN A; CHROMOGRANINS; COLLAGEN TYPE I; DISEASE PROGRESSION; GLYCOPROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; NEOPLASM STAGING; OSTEOPROTEGERIN; PEPTIDE FRAGMENTS; PHOSPHOPYRUVATE HYDRATASE; PREVALENCE; PROBABILITY; PROCOLLAGEN; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; TESTOSTERONE; TISSUE KALLIKREINS; TUMOR MARKERS, BIOLOGICAL;

EID: 22144473007     PISSN: 03008886     EISSN: None     Source Type: Journal    
DOI: 10.1080/03008880510030941     Document Type: Conference Paper

References (162)

1. Franks L. Latent carcinoma of the prostate. J Pathol Bacteriol 1954;68:603-16.
2. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996;30:138-44.
3. Wilson SS, Crawford ED. Screening for prostate cancer. Clin Prostate Cancer 2004;3:21-5.
4. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
5. Auvinen A, Rietbergen JB, Denis LJ, Schroder FH, Prorok PC. Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen 1996;3:97-104.
6. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.
7. Pearson JD, Carter HB. Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol 1994;152(5 Pt 2):1743-8.
8. Stenman U-H, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994;344:1594-8.
9. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78.
10. Finnish Cancer Registry. Mean annual numbers of new cancer cases in 1955-2001, by primary site and period, MALES. Available from: www.cancerregistry.fi/v2001/v20010003i.html
11. Hoedemaeker RF, Van der Kwast TH, Schroder FH. The clinical significance of a small focus of well-differentiated carcinoma at prostate biopsy. BJU Int 2003;92(Suppl 2):92-6.
12. Klotz L. Expectant management with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 2002;7:175-9.
13. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002;167:1231-4.
14. Allaf ME, Carter HB. Update on watchful waiting for prostate cancer. Curr Opin Urol 2004;14:171-5.
15. Zappa M, Ciatto S, Bonardi R, Mazzotta A. Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study. Ann Oncol 1998;9:1297-300.
16. Draisma G, De Koning HJ. MISCAN: estimating lead-time and over-detection by simulation. BJU Int 2003;92(Suppl 2):106-11.
17. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer. Part II. Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 1999;91:1025-32.
18. Etzioni R, Penson DF, Legier JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U. S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-90.
19. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-9.
20. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125-35.
21. Catalona WJ, Ramos CG, Carvalhal GF, Yan Y. Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology 2000;55:791-5.
22. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004;100:1397-405.
23. Schroder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R. Prostate-specific antigen-based early detection of prostate cancer-validation of screening without rectal examination. Urology 2001;57:83-90.
24. Auvinen A, Maattanen L, Finne P, Stenman UH, Aro J, Juusela H, et al. Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial. Int J Cancer 2004;111:940-3.
25. Stenman U-H, Leinonen J, Zhang WM, Finne P. Prostate-specific antigen. Semin Cancer Biol 1999;9:83-93.
26. Diamandis EP, Yousef GM, Clements J, Ashworth LK, Yoshida S, Egelrud T, et al. New nomenclature for the human tissue kallikrein gene family. Clin Chem 2000;46:1855-8.
27. Lundwall A. Characterization of the gene for prostate-specific antigen, a human glandular kallikrein. Biochem Biophys Res Commun 1989;161:1151-9.
28. Lovgren J, Rajakoski K, Karp M, Lundwall A, Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 1997;238:549-55.
29. Paju A, Bjartell A, Zhang WM, Nordling S, Borgstrom A, Hansson J, et al. Expression and characterization of trypsinogen produced in the human male genital tract. Am J Pathol 2000;157:2011-21.
30. Belanger A, van Halbeek H, Graves HC, Grandbois K, Stamey TA, Huang L, et al. Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate 1995;27:187-97.
31. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-63.
32. Zhang W-M, Leinonen J, Kalkkinen N, Dowell B, Stenman U-H. Purification and characterization of different molecular forms of prostate specific antigen in human seminal fluid. Clin Chem 1995;41:1567-73.
33. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76:1899-903.
34. Stenman UH. Prostate-specific antigen, clinical use and staging: an overview. Br J Urol 1997;1:53-60.
35. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
36. Abrahamsson PA, Lilja H, Falkmer S, Wadstrom LB. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 1988;12:39-46.
37. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-6.
38. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991;37:1618-25.
39. Leinonen J, Lövgren T, Vornanen T, Stenman U-H. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and the complex between prostate-specific antigen with a-1-antichymotrypsin. Clin Chem 1993;39:2098-103.
40. Pettersson K, Piironen T, Seppala M, Liukkonen L, Christensson A, Matikainen MT, et al. Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex. Clin Chem 1995;41:1480-8.
41. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
42. Stenman U-H, Leinonen J, Zhang W-M, Finne P, Wu P. The clinical importance of free prostate-specific antigen (PSA). Curr Opin Urol 1998;8:393-9.
43. Lilja H, Haese A, Bjork T, Friedrich MG, Piironen T, Pettersson K, et al. Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy. J Urol 1999;162:2029-34; discussion 2034-5.
44. Zhu L, Leinonen J, Zhang WM, Finne P, Stenman UH. Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha(1)- antichymotrypsin complex together with free or total PSA. Clin Chem 2003;49:97-103.
45. Zhang WM, Leinonen J, Kalkkinen N, Stenman U-H. Prostate-specific antigen forms a complex with and cleaves alpha 1-protease inhibitor in vitro. Prostate 1997;33:87-96.
46. Zhang W-M, Finne P, Leinonen J, Vesalainen S, Nordling S, Rannikko S, et al. Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. Clin Chem 1998;44:2471-9.
47. Finne P, Zhang W-M, Auvinen A, Leinonen J, Määttänen L, Rannikko S, et al. Use of the complex between prostate-specific antigen and α1-protease inhibitor in screening for prostate cancer. J Urol 2000;164:1956-60.
48. Allard WJ, Zhou Z, Yeung KK. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 1998;44(6 Pt 1):1216-23.
49. Horninger W, Cheli CD, Babaian RJ, Pritsche HA, Lepor H, Taneja SS, et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology 2002;60(4 Suppl 1):31-5.
50. Lein M, Kwiatkowski M, Semjonow A, Luboldt HJ, Hammerer P, Stephan C, et al. A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J Urol 2003;170(4 Pt 1):1175-9.
51. Chen Z, Chen H, Stamey TA. Prostate specific antigen in benign prostatic hyperplasia: purification and characterization. J Urol 1997;157:2166-70.
52. Mikolajczyk SD, Millar LS, Marker KM, Wang TJ, Rittenhouse HG, Marks LS, et al. Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia. Prostate 2000;45:271-6.
53. Hilz H, Noldus J, Hammerer P, Buck F, Luck M, Huland H. Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumors. Eur Urol 1999;36:286-92.
54. Peter J, Unverzagt C, Krogh TN, Vorm O, Hoesel W. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 2001;61:957-62.
55. Linton HJ, Marks LS, Millar LS, Knott CL, Rittenhouse HG, Mikolajczyk SD. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 2003;49:253-9.
56. Nurmikko P, Pettersson K, Piironen T, Hugosson J, Lilja H. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin Chem 2001;47:1415-23.
57. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Marks LS, Song W, et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 2000;60:756-9.
58. Piironen T, Lovgren J, Karp M, Eerola R, Lundwall A, Dowell B, et al. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem 1996;42:1034-41.
59. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Saeid MS, et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 1999;53:939-44.
60. Becker C, Piironen T, Pettersson K, Bjork T, Wojno KJ, Oesterling JE, et al. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J Urol 2000;163:311-6.
61. Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Huber A, Lummen G, et al. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. Urology 2000;55:481-5.
62. Haese A, Graefen M, Steuber T, Becker C, Pettersson K, Piironen T, et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate 2001;49:101-9.
63. Partin AW, Catalona WJ, Finlay JA, Darte C, Tindall DJ, Young CY, et al. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology 1999;54:839-45.
64. Bangma CH, Wildhagen MF, Yurdakul G, Schroder FH, Blijenberg BG. The value of ( -7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int 2004;93:720-4.
65. Haese A, Vaisanen V, Finlay JA, Pettersson K, Rittenhouse HG, Partin AW, et al. Standardization of two immunoassays for human glandular kallikrein 2. Clin Chem 2003;49:601-10.
66. Blijenberg BG, Wildhagen MF, Bangma CH, Finlay JA, Vaisanen V, Schroder FH. Comparison of two assays for human kallikrein 2. Clin Chem 2003;49:243-7.
67. Stenman UH. Standardization as a private enterprise. Clin Chem 2003;49:535-6.
68. Stamey TA, Ekman PE, Blankenstein MA, Cooper EH, Kontturi M, Lilja H, et al. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Scand J Urol Nephrol Suppl 1994;162:73-87.
69. Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993;71:3952-65.
70. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, et al. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996;178:437-41.
71. Kadmon D, Thompson TC, Lynch GR, Scardino PT. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 1991;146:358-61.
72. Tarle M, Rados N. Investigation on serum neurone-specific enolase in prostate cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay. Prostate 1991;19:23-33.
73. Abrahamsson PA, Falkmer S, Falt K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker". Pathol Res Pract 1989;185:373-80.
74. Kamiya N, Akakura K, Suzuki H, Isshiki S, Komiya A, Ueda T, et al. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur Urol 2003;44:309-14; discussion 314.
75. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-89.
76. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
77. Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, Kaaks R. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 2004;22:3104-12.
78. Finne P, Auvinen A, Koistinen H, Zhang WM, Maattanen L, Rannikko S, et al. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 2000;85:2744-7.
79. Endrizzi J, Optenberg S, Byers R, Thompson IM Jr. Disappearance of well-differentiated carcinoma of the prostate: effect of transurethral resection of the prostate, prostate-specific antigen, and prostate biopsy. Urology 2001;57:733 6.
80. Colao A, Marzullo P, Spiezia S, Ferone D, Giaccio A, Cerbone G, et al. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. J Clin Endocrinol Metab 1999;84:1986-91.
81. Oliver SE, Holly J, Peters TJ, Donovan J, Persad R, Gillatt D, et al. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening. Urology 2004;64:317-22.
82. Wu CP, Gu FL. The prostate in eunuchs. Prog Clin Biol Res 1991;370:249-55.
83. Lipsett MB. Estrogen use and cancer risk. J Am Med Assoc 1977;237:1112-5.
84. Stattin P, Lumme S, Tenkanen L, Alfthan H, Jellum E, Hallmans G, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 2004;108:418-24.
85. Stattin P, Soderberg S, Hallmans G, Bylund A, Kaaks R, Stenman UH, et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab 2001;86:1341-5.
86. Stattin P, Kaaks R, Johansson R, Gislefoss R, Soderberg S, Alfthan H, et al. Plasma leptin is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12:474-5.
87. Bok RA, Small EJ. Bloodborne biomolecular markers in prostate cancer development and progression. Nat Rev Cancer 2002;2:918-26.
88. Gutman E, Sproul E, Gutman A. Significance of increased phosphatase activity of bone at the site of osteoblastic metastases secondary to carcinoma of the prostate gland. Am Cancer 1936;28:485-95.
89. Huggins C, Hodges C. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
90. Wymenga LF, Groenier K, Schuurman J, Boomsma JH, Elferink RO, Mensink HJ. Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis. BJU Int 2001;88:231-5.
91. Koizumi M, Yonese J, Fukui I, Ogata E. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 2001;87:348-51.
92. Diaz-Martin MA, Traba ML, De La Piedra C, Guerrero R, Mendez-Davila C, De La Pena EG. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma. Scand J Clin Lab Invest 1999;59:125-32.
93. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000;82:858-64.
94. Kylmala T, Tammela TL, Risteli L, Risteli J, Kontturi M, Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 1995;71:1061-4.
95. Maeda H, Koizumi M, Yoshimura K, Yamauchi T, Kawai T, Ogata E. Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol 1997;157:539-43.
96. Noguchi M, Noda S. Pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol 2001;166:1106-10.
97. Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M, et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000;164:1248-53.
98. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68.
99. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82.
100. Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH, Corey E. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 2001;7:2977-83.
101. Jung K, Lein M, Stephan C, Von Hosslin K, Semjonow A, Sinha P, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004;111:783-91.
102. Eaton CL, Wells JM, Holen I, Croucher PI, Hamdy FC. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 2004;59:304-10.
103. Bellows CG, Aubin JE, Heersche JN. Initiation and progression of mineralization of bone nodules formed in vitro: the role of alkaline phosphatase and organic phosphate. Bone Miner 1991;14:27-40.
104. Fontana A, Delmas PD. Markers of bone turnover in bone metastases. Cancer 2000;88(12 Suppl):2952-60.
105. Pelger RC, Lycklama ANGB, Zwinderman AH, Hamdy NA. Estramustine phosphate combined with orchidectomy as first-line therapy in patients with prostate carcinoma. Effect of age on survival. Cancer 2002;94:2596-601.
106. Petrioli R, Rossi S, Caniggia M, Pozzessere D, Messinese S, Sabatino M, et al. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases. Urology 2004;63:321-6.
107. Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001;86:2787-91.
108. Meijer WG, van der Veer E, Willemse PH. Biochemical parameters of bone metabolism in bone metastases of solid tumors [review]. Oncol Rep 1998;5:5-21.
109. Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 2000;11(Suppl 6):S66-76.
110. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level
111. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
112. Määttänen L, Auvinen A, Stenman UH, Tammela T, Rannikko S, Aro J, et al. Three-year results of the Finnish prostate cancer screening trial. J Natl Cancer Inst 2001;93:552-3.
113. Van der Cruijsen-Koeter PW, van der Kwast TH, Schroder FH. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst 2003;95:1462-6.
114. Hakama M, Stenman UH, Aromaa A, Leinonen J, Hakulinen T, Knekt P. Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland. J Urol 2001;166:2189-91; discussion 2191-2.
115. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-94.
116. Antenor JA, Han M, Roehl KA, Nadler RB, Catalona WJ. Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J Urol 2004;172:90-3.
117. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
118. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993;71:2031-40.
119. Freedland SJ, Dorey F, Aronson WJ. Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy. Urology 2001;57:476-80.
120. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989;142:1011-7.
121. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989;141:873-9.
122. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;143:747-52.
123. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993;269:57-60.
124. Virtanen A, Gomari M, Kranse R, Stenman U-H. Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin Chem 1999;45:987-94.
125. Hugosson J, Aus G, Bergdahl S, Fernlund P, Frosing R, Lodding P, et al. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden. BJU Int 2003;92(Suppl 2):39-43.
126. Southwick PC, Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, et al. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J Urol 1999;162:1346-51.
127. Raaijmakers R, Wildhagen MF, Ito K, Paez A, de Vries SH, Roobol MJ, et al. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology 2004;63:316-20.
128. Aus G, Becker C, Lilja H, Khatami A, Pihl CG, Hugosson J. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3). Scand J Urol Nephrol 2003;37:466-70.
129. Babaian RJ, Fritsche HA, Evans RB. Prostate-specific antigen and prostate gland volume: correlation and clinical application. J Clin Lab Anal 1990;4:135-7.
130. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147(3 Pt 2):815-6.
131. Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000;56:255-60.
132. Finne P, Finne R, Auvinen A, Juusela H, Aro J, Määttänen L, et al. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology 2000;56:418-22.
133. Kikuchi E, Nakashima J, Ishibashi M, Ohigashi T, Asakura H, Tachibana M, et al. Prostate specific antigen adjusted for transition zone volume: the most powerful method for detecting prostate carcinoma. Cancer 2000;89:842-9.
134. Horninger W, Rogatsch H, Reissigl A, Volgger H, Klocker H, Hobisch A, et al. Correlation between preoperative predictors and pathologic features in radical prostatectomy specimens in PSA-based screening. Prostate 1999;40:56-61.
135. Djavan B, Remzi M, Zlotta A, Seitz C, Snow P, Marberger M. Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 2002;20:921-9.
136. Finne P, Finne R, Bangma C, Hugosson J, Hakama M, Auvinen A, et al. Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. Int J Cancer 2004;111:310-5.
137. Stephan C, Cammann H, Semjonow A, Diamandis EP, Wymenga LF, Lein M, et al. Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 2002;48:1279-87.
138. Vis AN, Kranse R, Roobol M, van der Kwast TH, Schroder FH. Serendipity in detecting disease in low prostate-specific antigen ranges. BJU Int 2002;89:384-9.
139. Finne P, Auvinen A, Aro J, Juusela H, Määttänen L, Rannikko S, et al. Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination. Eur Urol 2002;41:619-27.
140. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-9.
141. Fang J, Metter EJ, Landis P, Carter HB. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology 2002;59:889-93; discussion 893-4.
142. Komatsu K, Wehner N, Prestigiacomo AF, Chen Z, Stamey TA. Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population. Urology 1996;47:343-6.
143. Ross PL, Mahmud S, Stephenson AJ, Souhami L, Tanguay S, Aprikian AG. Variations in PSA doubling time in patients with prostate cancer on "watchful waiting": value of short-term PSADT determinations. Urology 2004;64:323-8.
144. Ito K, Yamamoto T, Ohi M, Takechi H, Kurokawa K, Suzuki K, et al. Natural history of PSA increase with and without prostate cancer. Urology 2003;62:64-9.
145. Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol 2001;165:1562-8.
146. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975-80.
147. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003;21:2163-72.
148. Pruthi RS, Johnstone I, Tu IP, Stamey TA. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer. Urology 1997;49:737-42.
149. Patel A, Dorey F, Franklin J, deKernion JB. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997;158:1441-5.
150. Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, De KJ, et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 2004;171(6 Pt 1):2260-4.
151. D'Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, et al. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst 2004;96:509-15.
152. Kelloff GJ, Coffey DS, Chabner BA, Dicker AP, Guyton KZ, Nisen PD, et al. Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. Clin Cancer Res 2004;10:3927-33.
153. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291:1325-32.
154. Cavanaugh SX, Kupelian PA, Fuller CD, Reddy C, Bradshaw P, Pollock BH, et al. Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy: prognostic value of a time-and-PSA threshold model. Cancer 2004;101:96-105.
155. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
156. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821-7.
157. Hansson J, Abrahamsson PA. Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann Oncol 2001;12(Suppl 2):S145-52.
158. Cussenot O, Villette JM, Valeri A, Cariou G, Desgrandchamps F, Cortesse A, et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996;155:1340-3.
159. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjolnerod OK, Waldum HL. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 1997;30:1-6.
160. Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000;88:2590-7.
161. Bollito E, Berruti A, Bellina M, Mosca A, Leonardo E, Tarabuzzi R, et al. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. Ann Oncol 2001;12(Suppl 2):S159-64.
162. Oefelein MG, Agarwal PK, Resnick MI. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol 2004;171:1525-8.